Spartina (tirzepatide) is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), as well as in those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in patients with known serious hypersensitivity to tirzepatide or any of its excipients. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide use. Healthcare professionals should evaluate patient history thoroughly before prescribing Spartina and provide appropriate counseling regarding potential symptoms of hypersensitivity reactions.

Patients should be counseled about the potential risk for medullary thyroid carcinoma (MTC) when using Spartina (tirzepatide) and should be informed about symptoms that may indicate thyroid tumors, such as a mass in the neck, difficulty swallowing, shortness of breath, or persistent hoarseness. Routine monitoring of serum calcitonin levels or thyroid ultrasound is not routinely recommended, as these methods have uncertain value for early MTC detection. Such monitoring may lead to unnecessary procedures due to low test specificity and the high background incidence of thyroid disease. Significantly elevated serum calcitonin values, typically above 50 ng/L, may indicate MTC and require further evaluation. Patients presenting with thyroid nodules upon physical examination or imaging should also undergo appropriate diagnostic assessment.

The use of Spartina (tirzepatide) has been associated with gastrointestinal adverse reactions, including events that may be severe. In a pooled analysis from two clinical trials (SURMOUNT-1 and SURMOUNT-2), severe gastrointestinal adverse reactions were reported more frequently in patients receiving Spartina compared to placebo. Specifically, severe gastrointestinal adverse reactions occurred in 1.7% of patients receiving 5 mg, 2.5% of patients receiving 10 mg, and 3.1% of patients receiving 15 mg, versus 1.0% in patients receiving placebo. Comparable rates of severe gastrointestinal adverse reactions were observed in clinical trials evaluating Spartina for weight reduction and for obstructive sleep apnea. Spartina has not been studied in patients with severe gastrointestinal diseases, including severe gastroparesis, and is therefore not recommended for use in these patients.

The use of Spartina (tirzepatide) has been associated with acute kidney injury, which may occur as a result of dehydration linked to gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea. Postmarketing reports from patients treated with GLP-1 receptor agonists have included cases of acute kidney injury and worsening of chronic renal failure, some of which required hemodialysis. These events have been documented even in patients without previously known renal disease. In most reported cases, acute kidney injury occurred in the context of gastrointestinal symptoms leading to volume depletion. Renal function should be monitored in patients receiving Spartina, particularly if they report adverse reactions that could increase the risk of dehydration.

Ask ChatGPT

Treatment with Spartina (tirzepatide) is associated with an increased occurrence of acute gallbladder disease. In pooled data from two clinical trials (SURMOUNT-1 and SURMOUNT-2), cholelithiasis was reported in 1.1% of patients treated with Spartina compared to 1.0% of those receiving placebo. Cholecystitis occurred in 0.7% of Spartina-treated patients versus 0.2% of placebo-treated patients, and cholecystectomy was reported in 0.2% of Spartina-treated patients, with no cases reported in the placebo group. Acute gallbladder events were observed in association with weight reduction, and similar rates of cholelithiasis were documented in clinical trials evaluating Spartina for both weight reduction and obstructive sleep apnea. If cholecystitis is suspected during treatment, gallbladder diagnostic studies and appropriate clinical follow-up are recommended.

Use of Spartina (tirzepatide) has been associated with gastrointestinal adverse reactions, including events that may be severe. In a pooled analysis of two clinical trials (SURMOUNT-1 and SURMOUNT-2), severe gastrointestinal adverse reactions occurred more frequently in patients treated with Spartina compared to those receiving placebo. Specifically, severe gastrointestinal adverse reactions were reported in 1.7% of patients receiving 5 mg, 2.5% of patients receiving 10 mg, and 3.1% of patients receiving 15 mg of Spartina, compared to 1.0% of patients in the placebo group. Comparable rates of severe gastrointestinal adverse reactions were observed in clinical trials evaluating Spartina for weight reduction and for obstructive sleep apnea. Spartina has not been studied in patients with severe gastrointestinal diseases, including severe gastroparesis, and its use is not recommended in these individuals.